Rafael Alcala‐Torano

ORCID: 0000-0002-5130-2557
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Transgenic Plants and Applications
  • Metal-Catalyzed Oxygenation Mechanisms
  • Electrocatalysts for Energy Conversion
  • Monoclonal and Polyclonal Antibodies Research
  • RNA and protein synthesis mechanisms
  • Metalloenzymes and iron-sulfur proteins
  • Chemical Synthesis and Analysis
  • Neuropeptides and Animal Physiology
  • Peptidase Inhibition and Analysis
  • Toxin Mechanisms and Immunotoxins
  • RNA modifications and cancer
  • Advanced Photocatalysis Techniques
  • CO2 Reduction Techniques and Catalysts
  • Supramolecular Self-Assembly in Materials
  • Receptor Mechanisms and Signaling
  • Fuel Cells and Related Materials
  • Covalent Organic Framework Applications
  • Biochemical and Structural Characterization

Tufts University
2022

Arizona State University
2013-2021

BioEnergetics (United States)
2013

While covalent drug discovery is reemerging as an important route to small-molecule therapeutic leads, strategies for the and engineering of protein-based irreversible binding agents remain limited. Here, we describe use yeast display in combination with noncanonical amino acids (ncAAs) identify variants single-domain antibodies (sdAbs), also called VHHs nanobodies, targeting botulinum neurotoxin light chain A (LC/A). Starting from a series previously described, structurally characterized...

10.1021/acschembio.2c00574 article EN ACS Chemical Biology 2022-12-02

The current trend in atmospheric carbon dioxide concentrations is causing increasing concerns for its environmental impacts, and spurring the developments of sustainable methods to reduce CO2 usable molecules. We report light-driven reduction water mild conditions by artificial protein catalysts based on cytochrome b 562 incorporating cobalt protoporphyrin IX as cofactor. Incorporation into scaffolds enhances intrinsic reactivity porphyrin toward proton CO generation. Mutations around...

10.3389/fmolb.2021.609654 article EN cc-by Frontiers in Molecular Biosciences 2021-04-15

10.1016/bs.mie.2016.06.001 article EN Methods in enzymology on CD-ROM/Methods in enzymology 2016-01-01

While covalent drug discovery is reemerging as an important route to small molecule therapeutic leads, strategies for the and engineering of protein-based irreversible binding agents remain limited. Here, we describe use yeast display, a high-throughput protein platform, in combination with noncanonical amino acids (ncAAs) identify variants single-domain antibodies (sdAbs), also called VHHs nanobodies, targeting botulinum neurotoxin light chain A (LC/A). Starting from series previously...

10.26434/chemrxiv-2022-lrj2r preprint EN cc-by-nc-nd 2022-06-22

Protein-based self-assembled nanostructures hold tremendous promise as smart materials. One strategy to control the assembly of individual protein modules takes advantage directionality and high affinity bonding afforded by metal chelation. Here, we describe use 2,2'-bipyridine units (Bpy) side chains template large structures (MW approx. 35 000 Da) in a metal-dependent manner. The are trimers independently folded 3-helix bundles, held together 2 Me(Bpy)3 complexes. assemblies stable thermal...

10.1002/bip.23233 article EN Biopolymers 2018-09-06
Coming Soon ...